Fennec Prescription drugs: Ruminating The Prospects And Necessity Of A Sale (NASDAQ:FENC)

Business for sale - For sale sign



​In late September, Fennec Prescription drugs (NASDAQ:FENC) announced it had obtained FDA-approval for Pedmark. This got here after two FDA rejections associated to manufacturing deficiencies. Fennec has spent over a decade getting Pedmark to market, leading to an accrued deficit of

Money & Equivalents $29.8 million
Quarterly Money Burn ~$8 million
Debt $25 million

Leave a Reply

Your email address will not be published. Required fields are marked *